Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + ixabepilone
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen of the small‑molecule tyrosine kinase inhibitor **dasatinib** and the epothilone B analog microtubule‑stabilizing chemotherapeutic **ixabepilone**, investigated in early‑phase clinical trials for advanced solid tumors and metastatic breast cancer. Dasatinib inhibits BCR‑ABL and Src family kinases, potentially enhancing chemosensitivity and reducing invasion, while ixabepilone stabilizes microtubules to induce mitotic arrest and apoptosis. Preclinical and clinical data reported synergy and modest clinical activity; a Phase I trial identified tolerable doses with frequent treatment‑related toxicities, and established schedules for combination therapy in solid tumors and metastatic breast cancer settings.[1][5][4][9]
- Other names
- dasatinib and ixabepilone
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on dasatinib + ixabepilone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + ixabepilone.